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Author Manuscript Published OnlineFirst on June 27, 2018; DOI: 10.1158/1078-0432. Sciences, and Mylan. M. Peck-Radosavljevic reports being an investigator for AbbVie, 73 ArQule-Daiichi, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Imclone, Lilly, MSD, 74 Novartis, and Roche, grant support from AbbVie, ArQule-Daiichi, Bayer, MSD, and Roche, 75 and acting as a speaker or advisor for Abbott, Bayer, Bristol-Myers Squibb, Boehringer Translational Relevance 97 The frequency of RAS mutations in hepatocellular carcinoma (HCC) is reported to be ~4%. 98 In this study, we report on the use of a liquid biopsy to prospectively screen patients with 99 HCC for RAS mutations using circulating tumor DNA for treatment with the MEK inhibitor 100 refametinib in monotherapy or in combination with sorafenib. The low prevalence of RAS 101 mutations in HCC was confirmed (4.4% of patients). RAS mutational status was confirmed 102 by next-generation sequencing using circulating tumor DNA, which allowed for the 103 determination of the mutational landscape in patients with HCC. The most frequently 104 detected mutations were in TERT, TP53, and β-catenin, confirming data reported in The 105 Cancer Genome Atlas. This is the first study using a liquid biopsy for large-scale mutational 106 testing, which offers the opportunity for comprehensive mutational analysis using a 107 non-invasive approach. 108 Research.
Author Manuscript Published OnlineFirst on June 27, 2018; DOI: 10.1158/1078-0432. Introduction 133 Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide (1,2), 134 and the prognosis for HCC remains extremely poor (2,3). The recommended standard of care 135 in advanced HCC is treatment with the multikinase inhibitor sorafenib (3-5). Lenvatinib has 136 been shown to be non-inferior to sorafenib in a recent phase III trial (6). In second-line, the 137 multikinase inhibitor regorafenib has been approved after showing significantly improved 138 survival versus placebo in patients who had disease progression on sorafenib (7). The kinase 139 inhibitor cabozantinib has also demonstrated promising survival improvements versus 140 placebo as second-line therapy in a phase III trial (8). Immunotherapy has shown promise in 141 HCC, with the immune checkpoint inhibitor nivolumab recently approved for the second-line 142 treatment of advanced HCC based on durable responses observed in a phase I/II trial (9). 143 Treatment with the monoclonal antibody ramucirumab has shown survival improvement 144 versus placebo in patients progressing to sorafenib with alpha-fetoprotein >400 ng/ml (10). 145 Poor prognosis and a lack of treatment options highlight a need for additional viable 146 treatment regimens in the advanced setting. 147 Refametinib (BAY 86-9766; Bayer AG, Berlin, Germany) is an oral, potent, non-adenosine 148 triphosphate competitive inhibitor targeting MEK 1 and 2 (11), which play a central role in 149 the RAS signal transduction cascade. RAS-MAPK signaling has been implicated in tumor 150 progression and dissemination in HCC (2). A phase I study of the combination of 151 refametinib with sorafenib in patients with advanced malignancies including HCC 152 demonstrated a favorable safety profile and pharmacokinetic profile at a maximum tolerated 153 dose of refametinib 50 mg twice daily in combination with sorafenib 400 mg twice daily (12). 154 The analysis of cell-free circulating tumor DNA (ctDNA) using beads, emulsion, Fifteen patients with RAS mutations were planned to be included in the first stage of each 186 study. The second stage was to be initiated if five or more of these patients had a confirmed 187 objective response according to mRECIST. 189 In the refametinib monotherapy study, the protocol was amended once, with changes 190 implemented globally. Prior cytotoxic chemotherapy was added as an exclusion criterion to 191 omit a population of overtreated patients who may have been different from patients 192 conventionally treated with sorafenib; this change affected eligibility criteria for RAS 193 mutation testing and treatment exclusion criteria. An exclusion criterion was also added 194 regarding women of childbearing potential to reduce the time gap between the pregnancy 195 evaluation and the beginning of treatment. 196 In the refametinib plus sorafenib study, the protocol was amended twice. Changes were 197 implemented globally and included the following amendments: patients with a corrected QT 198 interval >480 ms at the time of screening were excluded from the study because of the 199 potential for QT prolongation with sorafenib; the exclusion criterion regarding women of 200 childbearing potential was amended to reduce the time gap between the pregnancy evaluation 201 and the beginning of treatment; the exclusion criterion regarding systemic anticancer therapy 202 was clarified, as patients with prior systemic anticancer therapy were not eligible for this 203 Research. study. In addition, a dose-modification scheme for hepatotoxic events was included, because 204 hepatotoxicity is an "identified risk" for the refametinib-sorafenib combination. 205 Amendments to the statistical analysis plan for the refametinib plus sorafenib study included 206 the collection of survival data to be continued until the last patient's last visit instead of until 207 12 weeks after the last patient's first treatment, or earlier if all patients had withdrawn from 208 the study. A data rule was also added regarding tumor assessment by centralized blinded 209 reading; for cases with missing adjudication for patients who had completed or withdrawn 210 from treatment at the time of primary analysis, the worst-case approach was to be applied. ctDNA from plasma samples collected in the pre-treatment period was centrally evaluated for 240 RAS mutational status using BEAMing technology (13), with a limit of detection at 0.02% 241 mutant allele. Tumor assessments were performed at screening and every 6 weeks. 242 Treatment response was centrally assessed according to mRECIST for the primary endpoint, 243 and was also investigator-assessed according to mRECIST (18). Safety, including adverse 244 events (AEs) and concomitant medications, was monitored throughout the studies. Creatine In each study, it was estimated that approximately 350 patients were needed to be tested via 258 BEAMing to identify 15 patients with mutated RAS in stage 1, and that approximately 259 2300 patients would need to be tested via BEAMing to identify a sufficient number of 260 patients with mutated RAS to be treated in stage 2. 261 Descriptive statistics were calculated for the presented endpoints. 264 In the refametinib monotherapy study, 498 patients were enrolled at 58 study centers in 265 17 countries across Asia, Europe, and the USA from September 2013 to June 2014. RAS 266 mutational testing was performed in 493 patients (Fig. 1A) ; 32 (6.5%) had a RAS mutation. 267 In the refametinib plus sorafenib study, 820 patients were enrolled at 80 study centers in (n = 16) or refametinib plus sorafenib (n = 16). Reasons for patients not receiving treatment 273 are summarized in Fig. 1 . 274 In the refametinib monotherapy study, the median age was 69 years and the median time 275 since initial HCC diagnosis was 72.1 weeks (Table 1) . Nine patients (56.3%) had received 276 prior first-line sorafenib treatment. In the refametinib plus sorafenib study, the median age 277 was 67 years and the median time since initial HCC diagnosis was 32.2 weeks (Table 1) . 278 Demographics and baseline characteristics were similar between patients irrespective of RAS 279 mutational status in both studies.
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Of the 16 patients treated with refametinib monotherapy, no patient had a CR or PR when 282 centrally assessed according to mRECIST, and the ORR was 0% (Table 2) . One patient 283 (6.3%) achieved an unconfirmed PR and eight (50.0%) achieved stable disease; the disease 284 control rate was 56.3%. ORR was 0% by independent assessment according to RECIST 285 version 1.1: no patients had a CR or PR, 10 (62.5%) had stable disease, two (12.5%) had 286 disease progression, and four (25.0%) were not evaluable. The investigator-assessed ORR 287 was 0% according to mRECIST ( Supplementary Table S1 ) and RECIST version 1.1: 288 no patients had a confirmed or unconfirmed CR or PR, 10 (62.5%) had stable disease, 289 two (12.5%) had disease progression, and four (25.0%) were not evaluable. 290 Of the 16 patients treated with refametinib plus sorafenib, one patient (6.3%) achieved a 291 confirmed PR when centrally assessed according to mRECIST, and the ORR was 6.3% 292 (Table 2) . Two patients (12.5%) achieved unconfirmed PRs (confirmatory computed 293 tomography scan showed progression) and four (25.0%) had stable disease; the disease 294 control rate was 43.8%. Independent assessment according to RECIST version 1.1 reported 295 an ORR of 6.3%: one patient (6.3%) had a confirmed PR, six (37.5%) had stable disease, 296 Research.
Author Manuscript Published OnlineFirst on June 27, 2018; DOI: 10.1158/1078-0432.CCR-17-3588 five (31.3%) had disease progression, and four (25.0%) were not evaluable or had data 297 missing. Investigator-assessed ORR was 6.3% according to mRECIST (one patient [6.3%] 298 had a confirmed PR) ( Supplementary Table S1 ). The investigator-assessed ORR was also 299 6.3% according to RECIST version 1.1: one patient (6.3%) had a PR, one (6.3%) had an 300 unconfirmed PR, five (31.3%) had stable disease, six (37.5%) had disease progression, and 301 three (18.8%) had missing data. 302 In the refametinib monotherapy study, four patients (25.0%) had radiologic progression and 303 the median time to progression was 2.8 months ( Fig. 2A ). Seven patients (43.8%) in the 304 refametinib plus sorafenib study had radiologic progression and the median time to 305 progression was 2.8 months ( Fig. 2B ). 306 Duration of response could not be calculated in the refametinib monotherapy study because 307 no patient achieved a CR or PR. Duration of response based on central assessment in the 308 refametinib plus sorafenib study was 1.4 months for the one patient who achieved a 309 confirmed PR; this patient had a KRAS G35A point mutation. Duration of response was 310 2.7 months for the one patient who was investigator-assessed as achieving a confirmed PR; 311 this patient had a KRAS G38A mutation. 312 In the refametinib monotherapy study, nine patients (56.3%) had disease progression or died 313 and median progression-free survival was 1.9 months (Fig. 2C ). Eight patients (50.0%) died 314 and median overall survival was 5.8 months ( Fig. 2E ). In the refametinib plus sorafenib 315 study, 10 patients (62.5%) had disease progression or died and median progression-free 316 survival was 1.5 months ( Fig. 2D ). Nine patients (56.3%) died and median overall survival 317 was 12.7 months ( Fig. 2F ). (Table 3 ) and were considered drug-related in 13 patients (81.3%). 332 Treatment was permanently discontinued because of TEAEs in four patients (25.0%) and 333 were considered drug-related in three patients (18.8%). 334 With refametinib plus sorafenib, dose modifications were reported in 11 patients (68.8%) 335 with refametinib and 11 patients (68.8%) with sorafenib. TEAEs led to dose modification in 336 15 patients (93.8%) ( reported in one patient each (6.3%) ( Supplementary Table S3 ). 352 TEAEs occurred in all 16 patients (100%) receiving refametinib plus sorafenib (Table 3) . 353 Hand-foot skin reaction was reported in two patients (12.5%). seven patients (43.8%) had events of worst grade 3 and one patient (6.3%) experienced worst 373 grade 4 (increased CPK). One SAE of grade 5 was considered refametinib-related and RAS-mutant HCC compared with 1.5% in HCC patients with no RAS mutation (17). 396 In these studies, prospective testing for RAS mutations using ctDNA isolated from plasma 397 was a feasible, non-invasive approach for large-scale mutational testing in HCC patients. 398 The current findings support a previous report of the use of ctDNA to detect KRAS mutations 399 via BEAMing in a small study of patients with refractory colorectal carcinoma treated with 400 regorafenib (21), although KRAS mutational frequency was notably higher in the colorectal 401 carcinoma population (~40%) compared with that reported here (~5%). Overall, 59/1318 402 (4.4%) of the HCC patients screened had a RAS mutation. The RAS mutation rates reported 403 here are consistent with previous reports in this patient population (~5%) (22-25). It should 404 therefore be noted that the low RAS mutational frequency in this population suggests that 405 identifying RAS-mutant patients may be challenging in practice. 406 The primary efficacy variable was not met in the refametinib monotherapy study, with no 407 patient with mutated RAS achieving a CR or PR. In the refametinib plus sorafenib study, one 408 patient with mutated RAS achieved a PR, resulting in an ORR of 6.3%, which is broadly 409 similar to the ORR of 6.9% reported in the BASIL trial (17). The target for the first stage of the trials (≥5/15 patients with a CR or PR) was not reached; 411 therefore, these studies did not proceed to the planned evaluation of refametinib monotherapy 412 or combination therapy in a larger number of patients. Further exploration would be required 413 to understand the lower ORR with refametinib plus sorafenib in this study compared with 414 previous reports (17). These results suggest that the use of RAS mutational status as a 415 prognostic biomarker for treatment response to refametinib monotherapy or in combination findings in the combination study support those described for patients receiving refametinib 449 plus sorafenib in the BASIL trial (17), although median overall survival was increased in our 450 study (12.7 months vs. 9.5 months, respectively). 451 Median time to progression was the same across the refametinib monotherapy and 452 refametinib plus sorafenib studies (2.8 months), with similar median progression-free 453 survival observed between the studies (1.9 months and 1.5 months, respectively). However, 454 progression-free survival times were lower than previous reports (17). 455 Drug exposure was similar between both studies and similar to the median refametinib dose 456 observed in the BASIL study (17). The majority of patients in the refametinib plus sorafenib 457 study experienced AEs during cycle 1 that prevented sorafenib dose escalation to 800 mg per 458 day, which was also observed in the BASIL study (17). The majority of patients across both studies experienced AEs leading to dose modifications, which may have caused insufficient 460 drug exposure, potentially leading to reduced efficacy of both refametinib regimens. Overall, 461 median duration of treatment was relatively short in both trials (7 weeks and 8 weeks, 462 respectively), similar to that reported for the BASIL study (8 weeks) (17). 463 Overall, refametinib was tolerated as monotherapy and combination therapy, and the majority 464 of TEAEs were manageable in both studies. In patients receiving refametinib monotherapy, 465 the most common TEAEs of limb edema, fatigue, nausea, and vomiting were consistent with 466 the safety profile previously reported in a phase I study of refametinib (31). The high overall 467 incidence of grade 3 TEAEs irrespective of causality in both studies (68.8%) was similar to 468 that reported in the BASIL trial (60.0%) (17). Generally, the observed incidence and severity 469 of refametinib-related TEAEs observed with refametinib monotherapy were comparable with 470 data from the previous refametinib phase I study (31). Refametinib-related SAEs were less 471 frequent with refametinib monotherapy than with refametinib plus sorafenib (43.8% vs. 472 75.0%, respectively). Increased CPK grade ≥3 was the most common refametinib-related 473 SAE reported in both studies, consistent with reports of increased CPK as a class effect of 474 MEK inhibitors (32-34). 475 Compared with the known safety profile of sorafenib monotherapy (29,35), a higher 476 incidence of liver and gastrointestinal toxicities and rash was observed in patients who 477 received refametinib plus sorafenib. However, alopecia and hand-foot skin reaction were less 478 common compared with those reported for sorafenib monotherapy (14% vs. 12.5% and 21% 479 vs. 6.3%, respectively) (29), possibly due to the reduced exposure to sorafenib in the majority 480 of patients in our study. 481 Biomarker analysis of ctDNA analyzed by NGS showed the observed mutational landscape 482 to be consistent with published data for HCC (36) . The most common mutation was in the Assigned to treatment n = 16
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